Domenico Pastore
Bari, 70124, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Matrix Stiffness Regulates Diffuse Large B-Cell Lymphoma (DLBCL) Spheroid Formation in a Tunable 3D Chitosan Hydrogel Model.
Journal: Gels (Basel, Switzerland)
Published: June 16, 2026
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.
Journal: HemaSphere
Published: April 02, 2026
Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).
Journal: Bone marrow transplantation
Published: April 01, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).
Journal: Hematological oncology
Published: November 13, 2025
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?
Journal: Annals of hematology
Published: October 22, 2025
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.
Journal: American journal of hematology
Published: August 22, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Journal: Bone marrow transplantation
Published: July 24, 2025
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese.
Journal: Annals of hematology
Published: July 19, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 27, 2025
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP).
Journal: Leukemia research reports
Published: April 11, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 26, 2025
Last Updated: 09/26/2026